WakeMed Innovation Venture Fund

Overview

WakeMed Innovation Venture Fund (WIVF) is a venture capital fund established in 2020 through a partnership between WakeMed Health & Hospitals and Hatteras Venture Partners. The fund focuses on investing in early-stage healthcare companies that develop technologies aimed at enhancing patient outcomes, operational efficiency, and financial performance for WakeMed. WIVF combines Hatteras' venture discipline with WakeMed's clinical insight and operational expertise to support companies creating transformative solutions in medical devices, diagnostics, digital health, and patient experience. This collaboration enables early-stage companies to access subject-matter experts, pursue pilot opportunities, conduct research, and validate their solutions in real-world settings. The fund's mission is to accelerate innovations that deliver measurable benefits to patients, providers, and community health systems while generating competitive, venture-style returns for WakeMed as the fund's limited partner. Since its inception, WIVF has reviewed more than 300 early-stage healthcare opportunities and engaged over 100 WakeMed clinicians and operators in evaluations, pilots, and validation activities. In 2025, WIVF marked its fifth anniversary, underscoring how an actively engaged community health system as a limited partner and an institutional venture firm as fund manager can work together to advance healthcare innovation.

Investment Focus

• Early-stage healthcare companies developing technologies that improve patient outcomes and operational efficiency for WakeMed Health & Hospitals.

Portfolio Companies